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Competing Regulatory
Paradigms of
Racial Categorization in
International Drug
Development
Jonathan Kahn, J.D., Ph.D∗

I. Introduction
Two powerful dynamics are at the forefront of contemporary pharmaceutical
development: global outsourcing of clinical trials and pharmacogenomics. These
two dynamics come together in the regulatory arena through the development of
international guidelines to harmonize the production and use of clinical data
involving diverse ethnic and racial groups. Such guidelines both produce and are
produced by the drive to develop individually tailored medicines in a world
market.
While promulgated to promote more efficient pharmaceutical
development, such mandates may also have the unintended consequence of
reshaping cultural and ultimately legal understandings of race and ethnicity as
genetically distinct and bounded categories. The regulatory construction of race
and ethnicity as genetic has the potential to produce both skewed science and
discriminatory social policies.
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This article will examine the implications of U.S. federal and international
regulatory mandates in the construction and circulation of racial categories in
biomedical research and drug development. It will focus on the interface between
two regulatory mandates in particular: the International Conference on
Harmonization (ICH) Guideline Document E-5 on “Ethnic Factors in the
Acceptability of Foreign Clinical Data,”1 and the U.S. Food and Drug
Administration (FDA) “Guidance for Industry: Collection of Race and Ethnicity
Data in Clinical Trials.”2 The ostensible purpose of both of these guidelines is to
promote more efficient and economical development of new pharmaceutical
interventions. Underlying both Guidances is a presumption that race and ethnicity
are relevant variables in assessing the safety and efficacy of drugs in clinical trials.
Both Guidances also implicitly cast race and ethnicity as obstacles to be managed
and overcome in the course of getting new drugs to global markets as quickly and
cheaply as possible.
Ultimately, however, the Guidances are driven by different regulatory
considerations which place them in tension with one another. The ICH guideline’s
primarily concern is to “harmonize” different state regulatory regimes in the
international arena. Its goal is to enable clinical data produced in one jurisdiction
to be used in another jurisdiction for the purposes of drug registration.3 The FDA
guideline is primarily concerned with providing a standardized bureaucratic
classification for racial and ethnic categories such that clinical trial data can be
collected and reported in a consistent manner within the FDA’s jurisdiction.4 The
FDA, therefore, adopts the racial and ethnic categories promulgated by the U.S.
Office of Management and Budget – used most familiarly in the U.S. Census.5
These categories, the FDA notes, “were developed in response to the need to
enforce civil rights laws in education” and should “not be interpreted as being
scientific or anthropological in nature.” The FDA categories are therefore
theoretically to be understood as social not genetic in nature. The ICH E5
Guideline does not set forth particular ethnic categories per se, but rather
1.
2.
3.
4.
5.

International Conference on Harmonization, Ethnic Factors in the Acceptability of Foreign
Clinical Data, (Feb. 5, 1998), available at http://www.ich.org/LOB/media/MEDIA481.pdf
[hereinafter ICH E5].
U.S. Food and Drug Administration (FDA), Guidance for Industry: Collection of Race and
Ethnicity Data in Clinical Trials (2005), available at
http://www.fda.gov/cder/guidance/5656fnl.pdf [hereinafter FDA Guidance].
ICH E5, supra note 1, at 1.
FDA Guidance, supra note 2, at 1.
Id. at 3.
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elaborates a series of “ethnic factors” which include social/cultural practices,
physiological processes, and genetics which are posited as potential variants across
ethnic groups.
The ICH process is transforming global drug development and marketing, and,
in particular, is opening up the large Japanese market to pharmaceuticals tested in
the West. The FDA Guidance similarly promises to transform the production and
organization of racial and ethnic data in clinical trials for the U.S. market. As
pharmaceutical development goes global, however, the social classifications of the
FDA Guidance also promise to collide with the mixture of social, physiological
and genetic “factors” elaborated in the ICH guideline. These diverse classificatory
schemes cannot be easily reconciled. This paper will explore how concepts of race
and ethnicity are being produced and reproduced through this collision. It will
further explore how these distinct attempts to “regulate race” in a bureaucratic
context are shaping the development of global pharmaceutical markets.
Part II of the article will set forth the background to the ICH E5 regulatory
mandate and its distinct concepts of race and ethnicity. Part III will explore how
the ICH guidelines have already begun to affect global pharmaceutical
development. Part IV will set forth the background to the FDA guidelines on the
collection of racial and ethnic data for clinical trials. It will then go on to examine
the debates that arose around the adoption of the FDA guidelines, specifically as
they involved considerations of how the FDA guidelines might impact global
pharmaceutical development under the ICH regulatory regime. Part V will
conclude the article with an examination of the broader implications of this story
for the production of social and regulatory understandings of the nature of race and
ethnicity.

II. Background to the ICH E5 Guidelines
A. The ICH
The ICH, formally known as the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals for Human Use, was
formed in 1990 at a meeting in Brussels hosted by the European Federation of
Pharmaceutical Industries and Associations (EFPIA).6 Interested parties at the
meeting included representatives of the regulatory agencies and industry

6.

36

ICH, History and Future of ICH, http://www.ich.org/cache/compo/276-254-1.html
(last visited May 16, 2006).
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associations of Europe, Japan, and the USA.7 The formation of the ICH was born
out of concerns “over rising costs of health care, escalation of the cost of R&D
[Research & Development] and the need to meet the public expectation that there
should be a minimum of delay in making safe and efficacious new treatments
available to patients in need.”8 One underlying factor affecting all of these
concerns was the diverse regulatory standards imposed by the governments of the
major pharmaceutical markets in the US, the European Union (EU), and Japan.
Founding members believed that the harmonization of standards for product
development and regulatory approval would greatly increase the efficiency and
economy of drug development and pave the way for the creation of a truly global
pharmaceuticals market.9 More specifically, harmonization was seen as a means to
lower drug development costs, reduce the time necessary to bring new drugs to
new markets, improve regulatory efficiency, and minimize risks to research
subjects.10
The ICH is structured around the US, the EU, and Japan. These regions account
for approximately 80% of the global pharmaceutical market.11 By region, the
founding members were: US – the FDA and the Pharmaceutical Research and
Manufacturers of America (PhRMA), which represents the leading research-based
pharmaceutical and biotechnology companies in the United States; the EU – the
European Commission (representing the twenty-five members of the EU) and the
EFPIA, which is composed of twenty-five national pharmaceutical industry
associations (plus six associations with liaison status) and forty-three leading
pharmaceutical companies involved in the research, development and
manufacturing of medicinal products in Europe for human use; Japan – the
Ministry of Health, Labor and Welfare (MHLW) and the Japan Pharmaceutical
Manufacturers Association (JPMA), which represents ninety member companies
including all the major research-based pharmaceutical manufacturers in Japan.12
These groups play the primary role in ICH decision making.13 Additionally, there

7.
8.
9.
10.
11.
12.
13.

Id.
Id.
Id.
J. John Lee, Comment: What is Past is Prologue: The International Conference on
Harmonization and Lessons Learned from European Drug Regulations Harmonization,
26 U. PA. J. INT’L ECON. L. 151,155 (2005).
Carly Anderson et al., Bridging Studies in Asia and the Impact of the ICH E5 Guideline, 37
DRUG INFORMATION J. 107S (2003).
Id.
Id.
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are three observer organizations, the World Health Organization (WHO), Health
Canada, and the European Free Trade Association (EFTA) who nominate nonvoting participants to attend the ICH Steering Committee Meetings.14
B. ICH E5
Since its inception, the ICH has promulgated a series of “Guidelines” grouped
into three broad categories: Quality, Safety, and Efficacy. Additionally, the ICH
has adopted a “Common Technical Document” (CTD)15 which serves as a standard
form for drug licensing approval across all three ICH regions.16 A key
consideration for global drug development and registration involves the
acceptability of data in different regions. To address this issue, the ICH adopted
Guideline E5, “Ethnic Factors in the Acceptability of Foreign Clinical Data,” in
1998.17 ICH E5 is intended to facilitate drug registration in the different ICH
regions by recommending a framework for evaluating the impact of ethnic factors
on a drug’s safety and efficacy in a manner that will enable appropriate evaluation
of ethnic factors. The Guideline is premised on the “desirability of utilizing
foreign clinical data that meet the regulatory standards and clinical trial practices
acceptable to the region considering the application for registration.”18
In recent decades, ethnicity has become perceived as a barrier to the
globalization of pharmaceutical development and marketing. Japan, in particular,
has resisted the licensing of many drugs already licensed in the US and the EU on
the grounds that clinical data based on studies of safety and efficacy conducted in
“Caucasian” populations cannot be directly extrapolated to apply to the “Japanese”
population.19 As one senior Japanese hospital official put it:
Ethnic factors in a broad sense have been regarded as one of the unavoidable reasons to
have some barriers to the acceptance of foreign clinical data. Therefore, the problem of
“Ethnic Factors in the Acceptability of Foreign Clinical Data” has been regarded as a
difficult, but the most important, subject in the harmonization of the clinical field of
20
ICH.

14.
15.
16.
17.
18.
19.
20.

38

Id.
ICH, Common Technical Document, http://www.ich.org/cache/compo/276-254-1.html
(last visited May 18, 2006).
Lee, supra note 10, at 180.
ICH E5, supra note 1, at 1.
Id.
Anderson, supra note 11.
Chikayuki Naito, Ethnic Factors in the Acceptability of Foreign Clinical Data, 32 DRUG
INFORMATION J. 1283S (1998), available at
http://diahome.org/content/abstract/1998/dijs1227.pdf.
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A driving concern behind the development of ICH E5, therefore, was to allow
data from clinical trials conducted in the “predominantly Caucasian” patient
population of the West to be extrapolated to the population of Japan.21 Japan has
the second largest national drug market in the world22 but it has been historically
difficult for Western pharmaceutical companies to gain entry to the Japanese
market for drugs tested in the West.23 Japanese regulatory authorities have resisted
approving such drugs on grounds that they may work differently in Japanese
populations.24 Thus, for example, of the 149 drugs approved by the US FDA
between 1992 and 1996 (before ICH E5 was adopted in 1998), 51% were not
available to patients in Japan by 2000.25
A major objective of ICH E5 is to allow for the extrapolation of data produced
in one ICH region to a different region.26 It is hoped that providing a regulated
framework for such extrapolation will minimize the duplication of clinical data and
facilitate the acceptance of foreign clinical data in new regions.27 ICH E5 also
describes a mechanism known as “bridging studies” which allows for the use of
smaller, cheaper studies in a host region’s population as a basis for extrapolating
data from larger full-scale clinical studies about which the host region otherwise
has reservations.28 Bridging studies thus supplement existing data as basis for
extrapolation, in effect leveraging existing data into new regulatory regimes.
It is in relation to bridging studies that so-called “Ethnic Factors” become most
salient. ICH E5 is premised on the idea that it should not be necessary to repeat an
entire clinical drug development program in a new region.29 It provides for the
development of a “clinical data package” that would fulfill the regulatory
requirements of a new region based on data produced in the originating region.30
At this point, the only remaining barrier to acceptance would be the concerns of

21.
22.
23.
24.
25.
26.
27.
28.
29.
30.

Anderson, supra note 11.
Stanford Jhee and Edyta Frackiewiewicz, Bridging Strategies May Help Put Western Drugs
on the Japanese Market, APPLIED CLINICAL TRIALS, Sept. 1, 2003,
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=79907.
Carly Anderson and Faiz Kermani, Global Acceptability of Clinical Data –Fact or Fiction?
http://www.samedanltd.com/members/archives/EPC/Autumn2002/CarlyAnderson.htm,
(last visited Apr. 16, 2006).
Id. See also Jhee and Frackiewiewicz, supra note 22.
Anderson and Kermani, supra note 23.
ICH E5, supra note 1, at 2.
Id.
Id. at 2, 5.
Id. at 2.
Id. at 3.
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the relevant regulatory authority that “ethnic factors” might impede the
extrapolation of clinical data produced in one region to apply to the new region.
The concern here would be that populations from one region might have
significantly different responses to particular drug, either in terms of safety or
efficacy, than populations from another region. ICH E5 therefore both defines the
parameters of the ethnic factors to be considered in evaluating drug response, and
provides for conducting smaller “bridging studies” where necessary, to confirm
relevant safety and efficacy information in the new regions population.31
Regulatory authorities from the three ICH regions, however, are concerned
about population-based averages of drug response and the degree to which any
overall variation might be attributable to ethnic factors. Responses to any drug
may vary from individual to individual. Indeed, for every drug, there are some
individuals who will respond better or worse or not at all, depending in part on
their genes. Some genes also play a substantial role in regulating how the body
metabolizes as drug. Finding an optimal dosage for a particular drug may be aided
by determining whether a particular individual’s genetic profile would lead her to
metabolize a drug more quickly or slowly than another.32 One irony in the
promulgation of ICH E5 as a means to overcome regulatory barriers to the
adoption of new drugs in different regions, especially Japan, are studies showing
that that intra-ethnic variability in drug response is generally no greater than interethnic variability.33 Thus, as one study found,
Even when there may be a statistically significant difference between two or more ethnic
groups in a given pharmacokinetic parameter of a drug, it is unclear how such difference
relates to the total population variance in that parameter. In fact, previous surveys of
potential ethnic differences in pharmacokinetics relevant to drug development and
registration have suggested that in some cases, interethnic differences appear no larger or
34
smaller than intraethnic variations.

Another study conducted by the Japanese Ministry of Health and Welfare and
the Japanese Pharmaceutical Association examining eighty New Chemical Entities
approved both in Japan and in the West similarly found intraethnic differences
were greater than interethnic differences.35 Nonetheless, the concept of interethnic
31.
32.
33.
34.
35.
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Id. at 3, 5-7.
B. Evans et al., Creating Incentives for Genomic Research to Improve Targeting of
Therpies, 10 NATURE MED. 1298 (2004).
T. Bjornsson et. al., A Review and Assessment of Potential Sources of Ethnic Differences in
Drug Responsiveness, 43 J. OF CLINICAL PHARMACOLOGY 943, 944 (2003).
Id.
Helen Dumitriu, Impact of the ICH Guideline on Ethnic Differences, 32 DRUG
INFORMATION J. 141, 142 (1998).
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variation lies at the heart of ICH E5 and of the subsequent development of a new
industry in bridging studies that has emerged in order to facilitate the entry of
Western drugs into the Japanese market.36
ICH E5 defines “ethnic factors” as “factors relating to races or large populations
grouped according to common traits and customs.”37 It makes a further key
distinction between what it characterizes as “intrinsic” versus “extrinsic” ethnic
factors.38 It defines “intrinsic ethnic factors” as “factors that help define and
identify a subpopulation and may influence the ability to extrapolate clinical data
between regions. Examples of intrinsic factors include genetic polymorphism, age,
gender, height, weight, lean body mass, body composition, and organ
dysfunction.”39 In contrast, it defines “extrinsic ethnic factors” as “factors
associated with the environment and culture in which a person resides. Extrinsic
factors tend to be less genetically and more culturally and behaviorally
determined.”40 At first blush, this distinction seems straightforward and relatively
unproblematic. However, ICH E5 elaborates upon these definitions in a chart
presented in its appendix in a manner that is far more troubling.
Specifically, the chart locates race as an intrinsic genetic characteristic. That is,
it constructs race as some sort of genetic component of a larger category of
ethnicity. Intrinsic ethnicity, in this scheme is presented as encompassing both
genetic and other broader and more variable biological components, such as age,
disease and cardiovascular function – each of which can affect the absorption,
distribution, metabolism and excretion (ADME) of drugs. Extrinsic ethnicity here
refers to social, environmental and cultural factors – factors “extrinsic” to the
physical human organism. The chart is highly problematic for a number of
reasons.
First is the basic definition of what counts as an ethnic and/or racial group.
Race and ethnicity are not static objective categories. Rather they have changed
dramatically over time and across space. The U.S. Census is a prime example.
Since the first census in 1790, racial categories have changed over time to reflect
the social and political concerns of the day. The first census had four categories:
Free White Males, Free White Females, Other Free Persons, and Slaves.41 During

36.
37.
38.
39.
40.
41.

Jhee and Frackiewicz, supra note 22.
ICH E5, supra note 1, at 9.
Id. at 9-10.
Id. at 10.
Id. at 9.
MELISSA NOBLES, SHADES OF CITIZENSHIP: RACE AND THE CENSUS IN MODERN POLITICS
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the nineteenth century, additional categories that fell in and out of use included
Free Colored Persons, Black, Mulatto, Quadroon, Octoroon, Indian, Chinese, and
Japanese.42 The twentieth century saw a new proliferation of categories including
Hindu, Korean, and Negro.43
Second, whatever they are, race and ethnicity are not genetic. Scientists may
and do disagree on the utility of using particular racial or ethnic categories as
surrogates for genetic groupings, arguing about different frequencies of particular
genetic variations. But race and ethnicity themselves are not genetically coherent
concepts.44 Rather, they are best understood as complex and dynamic social
constructs.45 Indeed, since the 1970s, scientists have understood that race will
statistically explain only a small portion of human variation.46 As a recent editorial
in Nature Biotechnology asserted, “[r]ace is simply a poor proxy for the
environmental and genetic causes of disease or drug response. . . . Pooling people
in race silos is akin to zoologists grouping raccoons, tigers and okapis on the basis
that they are all stripey.”47
Third, as noted above,48 studies conducted largely in response to concerns
raised by ICH E5 have shown that variation in drug response is often greater within
ethnic groups, however defined, than across ethnic groups. This comports
naturally with the observation made in a 2001 editorial in the journal Nature
Genetics that, “scientists have long been saying that at the genetic level there is
more variation between two individuals in the same population than between
populations and that there is no biological basis for ‘race.’”49
Fourth, with respect to the specific application of the ICH E5 criteria, one study

42.
43.

44.
45.

46.
47.
48.
49.

42

28 (2000).
Id. at 28, 44.
Id. at 44. See also generally MARGO ANDERSON, THE AMERICAN CENSUS: A SOCIAL
HISTORY (Yale University Press 1988); Sandra Soo-Jin Lee et al., The Meaning of ‘Race’ in
the New Genomics: Implications for Health Disparities Research, 1 YALE J. HEALTH
POL’Y L. & ETHICS 33 (2001).
Francis Collins, What We Do and Don’t Know About ‘Race,’ ‘Ethnicity, ’Genetics and
Health at the Dawn of the Genome Era, 36 NAT. GEN., S13-15 (2004).
See, e.g., American Anthropological Association, Response to OMB Directive 15: Race and
Ethnic Standards for Federal Statistics and Administrative Reporting, Sept. 1997, available
at http://www.aaanet.org/gvt/ombdraft.; American Anthropological Association, Statement
on Race (1998), available at http://www.aaanet.org/stmts/racepp.htm [hereinafter AAA,
Statement].
Richard Lewontin, The Apportionment of Human Diversity, 6 EVOL. BIOL. 381, 381-84
(1972).
Editorial, Illuminating BiDil, 23 NAT. BIOTECH. 903, 903 (2005).
See supra text accompanying notes 32-35.
Editorial, Genes, Drugs and Race, 29 NAT. GEN. 239, 239 (2001), available at
http://www.nature.com/ng/journal/v29/n3/full/ng1101-239.html.
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noted that “considering the general nature of these guidelines, there is clearly the
potential for different regions or countries to apply different interpretations, thus
potentially defeating some of the goals of the guidelines.”50 This is in part because
the different ethnic groups are not always well characterized, and also because
even when clearly characterized the definitions often presume more homogeneity
within the group than is warranted.51
Finally, in a world rife with historical examples of stigma and discrimination
based on false constructions of particular groups as biologically different (and/or
inferior) the geneticization of race is fraught with peril.52 One need not identify
specific, immediate consequences that might flow directly from the ICH guidelines
to caution that the formal, regulatory adoption of genetic conceptions of race could
contribute to unintended and unforeseen negative consequences.

III. The Immediate Commercial Impact of ICH E5
In recent years an entire industry has grown up around global human subject
recruitment and research for clinical trials in drug development.53 Companies
known as Contract Research Organizations (CROs) span the globe on behalf of
Western pharmaceutical corporations looking to outsource clinical trials to more
economical venues, often in developing nations.54 These foreign sites are
attractive not only because trials are cheaper, but also because human subjects are
often easier to recruit, are more deferential to medical authority, and are “treatment
naïve,” that is, they are not already on other pharmaceutical therapies that might
mask or interfere with the effect of the drug being tested.55 CROs have become
big business as the pace of clinical outsourcing has accelerated. A recent study
shows that clinical outsourcing has become a significant basis for new growth
among major pharmaceutical corporations.56

50.
51.
52.
53.
54.
55.
56.

Bjornsonn, supra note 33, at 961.
Id. at 959-61.
The literature on this topic is vast and varied. See generally DANIEL KEVLES, IN THE NAME
OF EUGENICS (1998); STEPHEN JAY GOULD, THE MISMEASURE OF MAN (1996).
See generally Adriana Petryna, Ethical Variability: Drug Development and Globalizing
Clinical Trials, 32 AM. ETHNOLOGIST 183 (2005).
Id.; See also Jennifer Kahn, A Nation of Guinea Pigs, WIRED, Mar. 2006, available at
http://www.wired.com/wired/archive/14.03/indiadrug.html.
Id.
Wai Lang Chu, Clinical Outsourcing Drags Big Pharma Out of Doldrums,
DRUGRESEARCHER.COM, May 11, 2006,
http://www.drugresearcher.com/news/ng.asp?n=67643-tufts-outsourcing-clinical-trials.
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In the aftermath of the adoption of ICH E5 in 1998, a new variant of this
industry emerged – CROs dedicated to conducting bridging studies, largely
focused on gaining entry to the Japanese pharmaceutical market. Thus, for
example, Focus Clinical Drug Development (Focus), a CRO that split from
SmithKline Beecham in 1992, has developed a specialized service in bridging
studies which it advertises as providing “studies in healthy Japanese volunteers
outside Japan.”57 Focus notes that “[p]hase I studies involving both Japanese and
White volunteers are a key element for a rapid global drug development
strategy,”58 and asserts that it “can provide pharmaceutical and biotech companies
a more efficient way to conduct ICH-E5 compliant bridging studies outside
Japan.”59 Focus offers standing “panels” of “440 Healthy Japanese volunteers
(male/female)”60 most of whom are students in Europe, and “4,400 Healthy White
Volunteers (male/female)”61 who it defines as “people with origin in Europe
(including the western part of Russia), North Africa or Middle East.”62 These
panels recapitulate the problematic ethnic/racial categories underlying the ICH E5
and present the same problems discussed above.63 Nonetheless, Focus emphasizes
that “[o]ur experience shows that Phase I bridging studies can be conducted
outside Japan and based on our expertise are acceptable to the Japanese
authorities.”64 The concentration on “White” and “Japanese” panels is not
incidental. ICH E5 and bridging studies are designed primarily to provide an
avenue for Western pharmaceutical corporations to gain access to the lucrative
Japanese market which hitherto had used concerns about ethnic variation in drug
response as a non-economic barrier to trade.
Similarly, Richmond Pharmacology bills itself as the “largest provider of
Japanese/Caucasian bridging studies in Europe.”65 Clients of Richmond’s bridging
studies include “US and European companies that want to launch into the Japanese

57.
58.
59.
60.
61.
62.
63.
64.
65.

44

Focus Clinical Drug Development, Bridging Studies, http://www.bridgingstudies.de/ (last
visited Sept. 20, 2006).
Focus Clinical Development, Introduction: Bridging Studies,
http://www.bridgingstudies.de/html/bridgingstudies.html (last visited Sept. 20, 2006).
Id.
Focus Clinical Development, Panels and Recruitment,
http://www.bridgingstudies.de/html/panel.html (last visited Sept. 20, 2006).
Id.
Id.
See supra text accompanying notes 41-51.
Focus Clinical Development, Our Offer, http://www.bridgingstudies.de/html/offer.html
(last visited Sept. 20, 2006).
Bridging Studies from Richmond Pharmacology, Ltd., Welcome,
http://www.bridgingstudies.com/ (last visited Sept. 20, 2006).
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pharmaceutical market.”66 Richmond boasts “a dedicated in-house Japanese
recruitment department, supported by a specialized marketing strategy and the
bespoke brand trials4japanese. Through this innovative approach, we receive circa
250 enquiries per month from potential Japanese volunteers.”67
These CROs construct their bridging studies around a presumption of intrinsic
difference between the “Japanese” and “White” or “Caucasian” members of their
human subjects panels. Such studies have provided the basis for successful drug
applications to Japanese regulatory authorities. Ironically, however, Chikayuki
Naito, Counselor to the Tokyo Teishin Hospital and Technical Advisor to the
Japanese Organization for Pharmaceutical Safety and Research, has noted that
intrinsic differences in drug response are likely nowhere near as significant as
extrinsic factors such as medical practice.68
Studies of the early effects of ICH E5 published in 2002 by CMR International,
(which describes itself as “the foremost provider of R&D performance metrics to
the global pharmaceutical industry”69) found “little effect on the number of trials
conducted in the EU and US,”70 but also indicated an industry-wide belief that ICH
E5 was expected to have “positive effects in terms of reducing the number of
patients required for trials conducted in Japan,”71 and would “lead to a reduction in
costs and development times for new drugs.”72 One of the CMR studies noted that
until the introduction of ICH E5 “repeat clinical trials were a fact of life in drug
development if a company wished to market a drug in more than one ICH
region.”73 ICH E5 marked a turning point in global drug development with Pfizer
gaining approval of Viagra® in Japan less than a year after the guideline was
finalized.74 Between 1999 and 2003, with Viagra leading the way, twenty new
drug applications were approved in Japan based on bridging studies and an

66.
67.
68.
69.
70.
71.
72.
73.
74.

Bridging Studies from Richmond Pharamcology, Ltd., Who We Work With,
http://www.bridgingstudies.com/who/ (last visited Sept. 20, 2006).
Bridging Studies from Richmond Pharamcology, Ltd., Volunteer Panels,
http://www.bridgingstudies.com/volunteers/ (last visited Sept. 20, 2006).
Chikayuki Naito, Necessity and Requirements of Bridging Studies and Their Present Status
in Japan, 38 INT’L J. CLINICAL PHARMACOL. & THER. 80, 80-81 (2000).
CMR International, Home: About Us, http://www.cmr.org/ (last visited Sept. 20, 2006).
Carly Anderson, Neil McAulsane & Stuart Walker, R&D Briefing No. 36: The Impact of
the ICH E5 Guideline on Global Drug Development, 36 CMR INT’L 1, 5 (2002), available
at http://www.cmr.org/pdf/r_d36.pdf.
Anderson and Kermani, supra note 23.
Id.
Id.
Id.
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additional twenty-four were approved using important foreign data as references,
leading one study to conclude that “the bridging strategy is becoming a common
and practical basis for the decision making of marketing approvals of new drugs in
Japan.”75 Another 2002 study of the ICH E5 noted that its “impact has been felt
particularly in Japan, but as the E5 bridging strategies develop, the positive impact
will be felt over a wide area in Pan-Asia and beyond to the rest of the world.”76

IV. The FDA Guidelines
In January 2003, the FDA announced the promulgation of a Draft Guidance for
Industry on the Collection of Race and Ethnicity Data for Clinical Trials for FDA
Regulated Products.77 After notice and comments, the FDA issued the final
guidance September, 2005.78 Before discussing the Guidance in detail, it is
important to note that it emerged out of a longstanding concern to produce better
data that would address the very real problem of health disparities in the United
States. Prominent federal mandates leading up the Guidance include the NIH
Revitalization Act of 1993, which directed the NIH to develop guidelines for
including women and minorities in NIH-sponsored clinical research,79 and the
Food and Drug Modernization Act of 1997 (FDMA) which directed the FDA to
examine issues related to the inclusion of racial and ethnic groups in clinical trials
of new drugs.80 The FDMA led to the promulgation of the FDA Guidance and the
NIH has also issued detailed guidelines and guidance mandating certain procedures
and practices concerning the inclusion of ethnic and racial minorities in clinical
trials.81
Thus, for example, the NIH “Policy on Reporting Race and Ethnicity Data”

75.
76.
77.
78.
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states, inter alia, that, the “NIH requires all grants, contracts, and intramural
projects conducting clinical research to address the Inclusion of Women and
Minorities. . . . Investigators are instructed to provide plans for the total number of
subjects proposed for the study and to provide the distribution by ethnic/racial
categories and sex/gender.”82 Similarly, the FDA recommends that individuals or
corporations submitting drug approval applications use “a standardized approach
for collecting and reporting race and ethnicity information in clinical trials
conducted in the United States and abroad for certain FDA regulated products.”83
As any federally funded researcher knows, these mandates impose significant
requirements and provide incentives to identify and collect research data according
to categories of race and ethnicity.
The federally mandated racial and ethnic categories, however, are not
biomedical in origin; rather they derive from the Office of Management and
Budget’s (OMB) 1997 “Revisions to the Standards for the Classification of Federal
Data on Race and Ethnicity.”84 These standards set forth “five minimum
categories for data on race: American Indian or Alaska Native, Asian, Black or
African American, Native Hawaiian or Other Pacific Islander, and White.”85
There are “two categories for data on ethnicity: ‘Hispanic or Latino,’ and ‘Not
Hispanic or Latino.’”86 These categories provide the basis for the classification of
all federal data on race and ethnicity, most notably, the census.
The OMB Standards, however, contain an important caveat: “The racial and
ethnic categories set forth in the standards should not be interpreted as being
primarily biological or genetic in reference.” 87 These categories were developed to
serve social, cultural, and political purposes. When the federal government
requires biomedical researchers and clinicians to import these social categories into
explicitly biological and/or genetic contexts, it is creating a structural situation in
which social categories of race and ethnicity may easily become confused and
conflated with biological and genetic categories in day to day practice.
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NATIONAL INSTITUTES OF HEALTH, NIH POLICY ON REPORTING RACE AND ETHNICITY
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In a “Talk Paper” discussing the issuance of the Draft Guidance in 2003, the
FDA elaborated upon their nature and purpose:
FDA regulations require drug sponsors to present an analysis of data according to age,
gender and race. An analysis of modifications of dose or dosage intervals for specific
groups is also required when manufacturers submit a new drug application for approval by
FDA. To accomplish this, FDA recommends that the drug manufacturers use the OMB
race and ethnicity categories during clinical trial data collection to ensure consistency in
88
evaluating potential differences in drug response among racial and ethnic groups.

Consistency is a key theme throughout the Draft Guidance. It exhibits a general
concern to regularize the collection and submission of data on race and ethnicity
across the spectrum of clinical trials and the drug development process. The Draft
Guidance specifically recommends the use of the OMB categories of race and
ethnicity, first, to “help ensure consistency in demographic subset analyses across
studies,” and second to help evaluate “potential differences in the safety and
efficacy of pharmaceutical products among population groups.”89 The Guidance
elaborates the rationale for this concern by referencing some studies that show on
average members of certain OMB racial groups may respond differently to certain
drug than members of other OMB racial groups.90 That is, the Guidelines connect
race and physiology. This in itself is highly problematic, as discussed above in
reference to the ICH E5 definition of race.91
The FDA Guidance contains the OMB caveat that its racial and ethnic
categories are not to be interpreted as biological or genetic, but its
recommendations, being based on physiological processes, nonetheless exist in
tension with it. This tension was recognized and seized upon by many
pharmaceutical companies in offering comments to the Draft Guidelines in 2003.
The response of pharmaceutical companies, however, was not uniform. Large
pharmaceutical companies with global marketing concerns focused in particular on
inconsistencies between the FDA mandated use of the distinctively American
OMB categories of race and ethnicity (e.g. “African American,” “Hispanic”) and
those used internationally in other ICH regions.92 Their comments tended to call
for a more sophisticated use of population categories that could be more easily
integrated with the structure of ICH E5 and more readily translatable across
88.
89.
90.
91.
92.
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FDA, FDA TALK PAPER: FDA ISSUES GUIDANCE FOR COLLECTION OF RACE AND
ETHNICITY DATA IN CLINICAL TRIALS FOR FDA REGULATED PRODUCTS (2003), available
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Id. at 3.
See supra text accompanying notes 41–51.
See infra pp. 24–26.

PP 34-56 KAHN (AA)

12/9/2006 11:25 AM

Harmonizing Race 49

regions.93 Smaller biotechnology companies tended to be less concerned with the
international ramifications of the Guidance but rather urged the adoption of new
genetic technologies to provide more precise population categories for the
collection of data.94
Generally speaking, comments submitted by pharmaceutical corporations
expressed concern over (1) inconsistent definitions of race and ethnicity, (2)
questionable accuracy of definitions of race and ethnicity, (3) the negative impact
that using OMB categories of race and ethnicity might have on global trial
recruitment, and (4) the creation of unnecessary and unscientific differences
among populations through the use of inappropriate racial and ethnic categories.
Underlying the concerns of large pharmaceutical corporations in particular was a
perceived need to develop a globally applicable standard for the collection of racial
and ethnic data – clearly more inline with the mandate of ICH E5. In short, where
the ethnic categorizations of ICH E5 were perceived as opening up global markets,
the OMB-based racial and ethnic classifications of the FDA Guidance were
perceived as a potential barrier to globalization of drug markets.
A. Inconsistent Definitions
The Pharmaceutical Research and Manufacturers of America (PrHMA)
describes itself as representing “the country’s leading pharmaceutical research and
biotechnology companies, which are devoted to inventing medicines that allow
patients to live longer, healthier, and more productive lives.”95 It opened its
comments to the FDA Draft Guidance with an admonition that “for these
categories to be valuable globally and to permit identification of ethnic differences,
there should be only one set of agreed ethnic/racial categories.”96 It therefore
recommended that the issue be brought to the ICH as a forum for the development
of globally consistent categories.97
Comments submitted by Pharmacia98

93.
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Id.
PhRMA, About PhRMA, http://www.phrma.org/about_phrma/ (last visited Sept. 25, 2006)
PHRMA, PHRMA COMMENTS/RECOMMENDATIONS -DRAFT GUIDANCE FOR INDUSTRY ON
THE COLLECTION OF RACE AND ETHNICITY DATA IN CLINICAL TRIALS FOR FDA
REGULATED PRODUCTS 1 (2003), available at
http://www.fda.gov/ohrms/dockets/dailys/03/Apr03/040103/8005b2dc.pdf.
Id.
PHARMACIA, PHARMACIA’S 5 MAR. 2003 COMMENTS RE GUIDANCE FOR INDUSTRY COLLECTION OF RACE AND ETHNICITY DATA IN CLINICAL TRIALS (2003), available at
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(subsequently acquired by Pfizer) largely replicated comments submitted by
PhRMA, and focused in particular on the myriad ways in which the Guidance
threatened to obstruct pharmaceutical globalization. With regard to inconsistent
definitions of race and ethnicity, Pharmacia observed that,
The OMB race and ethnicity categories can be used only in the US, not in the EU or in
Japan; this is especially true for the ethnicity questions (Hispanic/Latino vs. Not
Hispanic/Latino). A definition of the ethnicity varies among the ICH countries, as well as
non-ICH countries. There will be more opportunities for the US to utilize foreign clinical
data in evaluating safety and efficacy of new drugs in the future. Therefore, it is
recommended that the race and ethnicity categories should be more scientific and globally
accepted so that the data comparison becomes more meaningful and provides valuable
information in evaluating potential differences or similarities in safety and efficacy of new
99
drugs among population subgroups.

There is a clear recognition here that the OMB definitions of race and ethnicity
are not static, scientifically objective categories. Pharmacia (and PhRMA) is
concerned that imposing the US regulatory definitions of race on the
pharmaceutical industry will inhibit the globalization of pharmaceutical markets.
Its comments explicitly reference the ICH and later employ the E5’s distinction
between intrinsic and extrinsic factors in evaluating the significance of race and
ethnicity in drug development.100 Ironically, though, the comments also assume
that it will be somehow possible to develop categories of race and ethnicity that are
“more scientifically and globally accepted.” The key focus here seems really to be
on global acceptance – hence the reference to the ICH structure. Comments
submitted by Abbot Laboratories expressed a similar concern that the OMB
categories were “oversimplified” and “vague,” and urged that the FDA
“recommend a better definition of race and ethnicity that can be understood by a
subject in a study and be consistent across the board.”101 Bristol-Meyers Squibb
also noted that the Guidance’s “proposed ethnicity and racial categories may be
understood differently in different parts of the world,” and urged the development
of “better defined categories.”102 Thus, for example, it proposed that the OMB

vol1.pdf [hereinafter PHARMACIA COMMENTS RE GUIDANCE].
99. Id. at 1.
100. Id.
101. ABBOTT LABORATORIES, COMMENTS ON THE DRAFT GUIDANCE FOR INDUSTRY ON THE
COLLECTION OF RACE AND ETHNICITY DATA IN CLINICAL TRIALS FOR FDA REGULATED
PRODUCTS 3, (2003), available at
http://www.fda.gov/ohrms/dockets/dailys/03/Mar03/032703/80059c93.pdf.
102. BRISTOL-MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE, RE: DOCKET NO. 02D0018, DRAFT GUIDANCE FOR INDUSTRY ON THE COLLECTION OF RACE AND ETHNICITY
DATA IN CLINICAL TRIALS FOR FDA REGULATED PRODUCTS AVAILABILITY, (2003)
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category of “Black or African American” be revised to “Black, of African heritage
or African American.”103 Given the OMB’s own caveat that its categories are not
genetic or biological, the clear concern is such a proposal is not to present a more
“scientific” definition of race but rather to produce a more globally acceptable
definition. The two are not necessarily the same.
Of all the OMB categories incorporated in the Guidance’s mandate, the
ethnicity category of “Hispanic or Latino” caused particular concern in terms of
consistent global application. Bristol Meyers Squibb noted that, “the requirement
that Hispanic or Latino versus not Hispanic or Latino ethnicity be collected even in
trials that are conducted entirely outside the US seems contradictory to the spirit of
the ICH guidelines. If ethnicity designations, as per the guidance, are to reflect the
sociocultural construct of the society, then the proposed category is generally
inappropriate outside the United States.”104 Again, there is a patent concern for
potential conflict with the ICH E5 guidelines and resulting barriers to the efficient
globalization of markets.
B. Questionable Accuracy
The asserted inappropriateness of the Latino/Hispanic category in a global context
was also used to highlight the questionable accuracy of the Guidance’s
terminology. Thus, Pharmacia argued that “[t]he terms Hispanic and Latino will
not have the same meaning outside the U.S. as they do within the U.S. According
to the definition, Spaniards are considered Hispanic, but they are both culturally
and racially more similar to French than Mexicans.”105
Similarly, Bristol Meyers Squibb notes that, “terminology – like ‘Latino’ –
can be confusing outside the United States, while the medical relevance of such
category is not demonstrated inside the US.”106 Pharmacia goes on to make similar
criticisms of the accuracy of the OMB categories noting that “there is no
distinction among the Asian group, which may be more genetically variable.”107 In
mentioning similarity and difference, medical relevance, and genetic variability,
these comments go beyond the earlier stated concern for globally consistent

available at www.fda.gov/ohrms/dockets/dailys/03/Mar03/032603/02d-0018-c000006-01vol1.pdf.
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definitions to the basic scientific accuracy of the categories themselves. And yet,
after these criticisms, the corporations do not call upon the FDA to reject such
classificatory schemes as inherently lacking “medical relevance” for drug
development, but rather simply suggests developing more globally applicable,
uniformly adoptable ethnic and racial categories – categories, in short, whose
primary purpose is to serve efficient globalization rather than accurate science.
Significantly, however, smaller biotechnology companies specializing in
genetic research urged a different approach to overcoming similar problems of
definitional accuracy. These companies, notably Genaissance Pharmaceuticals and
DNAPrint Genomics do not have the global reach of corporations such as
Pharmacia or Bristol Meyers Squibb. Genaissance, for example, describes itself as
“a biotechnology company whose business is based on the discovery of human
gene variation for the development of personalized medicines.”108 It markets its
technology to large pharmaceutical corporations rather than engaging directly in
global drug development and marketing.109 The focus of their criticisms of the
FDA Guidance, therefore, was less on developing globally consistent categories of
race and ethnicity, and more on using their own proprietary genetic technologies to
provide purportedly more scientifically objective and accurate definitions of race
and ethnicity.
In its comments on the OMB Categories employed by the Draft Guidance,
Genaissance focused on genetic accuracy, observing that,
Although these categories may be useful for national demographics, they are substandard
with regard to the state-of-the-art in genetic analysis of ancestry. In a population such as
the United States that increasingly is mixed, the boundaries between these classifications
are likely to be blurred further. For example, Genaissance has conducted genetic analysis
of Hispanic populations from Florida and California. It is very clear that the label
“Hispanic” encompasses individuals with African descent and Native American descent,
110
as well as Caucasian descent.

Genaissance here very subtly introduces the concept of genetic ancestry as a
metric to assess the validity of the OMB categories of race and ethnicity. In
speaking of blurring and mixing, the comment implies that there are some
underlying genetically pure categories of “Caucasian,” “African,” and “Native

108. GENAISSANCE PHARMACEUTICALS, FEDERAL REGISTER DOCKET NO. 02D-0018,
COMMENTARY ON THE FDA GUIDANCE FOR INDUSTRY “COLLECTION OF RACE AND
ETHNICITY DATA IN CLINICAL TRIALS” (2003), available at
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American” – a very problematic assertion. Moreover, focusing, like many other
comments, on the term “Hispanic” as mixed and blurred, it sets forth a straw man.
It is precisely because of the lack of conceptual congruence between the term
Hispanic/Latino and terms such as African, Caucasian, and Native American that
the OMB separated out ethnic from racial categories.
Nonetheless, Genaissance recognizes the questionable accuracy of using any
racial or ethnic categories in the context of pharmaceutical research and
development. Commenting on the Draft Guidance’s discussion of the relation
between race and drug metabolism, Genaissance notes that, “the link between
these clinical outcomes and race is anecdotal at best and discriminatory at worst.
New genetic technologies offer much more precise relationships between the
genotype of an individual and the clinical management of disease.”111 Genaissance
presents a solution to this problem in the form of its proprietary technology which
it asserts “would afford a high-resolution genetic identification of ancestry,
consistent analysis of ethno-geographic backgrounds, and possible use directly to
diagnostics for improvement of drug therapy.”112 That is, it urges the FDA to
replace OMB categories of race with genetic categories of ancestry, recommending
“the adoption of new genetic systems for ancestry determination rather than
antiquated and potentially inaccurate racial denominations.”113 Unlike the
suggestions from large pharmaceutical corporations, Genaissance here is less
concerned with global uniformity per se and more with the purported scientific
accuracy of the categories – accuracy to be provided by its own technology. One
basic problem with Genaissance’s claim to more rigorous scientifically based
categories of ancestry is that its own discussion of them is premised on definitions
of ancestral population that essentially replicate the OMB categories. Thus, in
discussing its genetic analysis of samples from US populations, it groups the
samples as “African American, Asian, Caucasian, and Hispanic/Latino.”114
In a similar vein, the comments from DNAPrint Genomics (which describes
itself as “an applied science company focused on the development and marketing
of innovative genetic testing products and services,”115) urge that “for the sake of
science and the health of us all . . . it is time to incorporate molecular
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anthropological data metrics”116 to supplement the OMB categories in the
collection of racial and ethnic data for clinical trials. It argues that its own
proprietary genetic concept of “Biogeographical Ancestry”117 (BGA) is better
suited for evaluating drug response than the OMB categories of race and ethnicity.
Like Genaissance, DNAPrint emphasizes the lack of accuracy inherent in selfreporting of race and suggests “that the FDA should pay more attention to
molecular characterization of population structure when evaluating and assisting
with the construction of clinical trials.” 118
Ironically, the genetic approaches taken by Genaissance and DNAPrint comport
well with ICH E5’s own categorization of race as an intrinsic genetic factor.
However the genetic approaches also suffer from the same dangers and
inaccuracies as the ICH E5 definition as discussed above,119 despite the patina of
scientific rigor layered upon them in the comments. In the end, where big
pharmaceutical corporations simply want to regularize race and ethnic categories
in whatever form they take so as to facilitate global drug development, small
biotech companies want to take control of the actual process of racial and ethnic
categorization and transform it into a function of genetics.
C. Negative Impact on Global Trial Recruitment
Beyond inconsistency and inaccuracy, large pharmaceutical companies also
expressed a pragmatic concern that being required to collect data according to the
OMB categories could have a significant detrimental impact on their ability to
recruit human subjects for clinical trials in a global environment. Here again, the
category of Hispanic/Latino was of particular concern. Pharmacia addressed this
issue most directly, noting that
Asking subjects about their race/ethnicity may be very sensitive in many circumstances
and could be viewed as a bureaucratic burden. Conducting a study in Japan, e.g., and
asking a subject whether they are Hispanic may result in patients taking questionnaires less
120
seriously and compromising other data being collected.

The specific reference to Japan echoes discussions surrounding the adoption of

116. DNAPrint Genomics, Inc. Docket: 02D-0018 - Collection of Race and Ethnicity Data in
Clinical Trials for FDA Regulated Products; Draft Guidance, Comment Number: EC-2,
(April 2, 2006), available at
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ICH E5 regarding the need to open up Japanese markets to Western
pharmaceuticals. Companies wishing to conduct bridging studies in Japan in
accordance with the ICH E5 guidelines certainly would not want their efforts
complicated or even subverted by the dictates of the FDA Guidance. Recruiting
human subjects for clinical trials is difficult under the best of circumstances. In a
commercial environment where ever increasing numbers of clinical trials are being
outsourced to countries around the world, Pharmacia here recognizes that the
regulatory construction of race and ethnicity may pose as great a barrier to the
globalization of markets as the medical construction of racial and ethnic difference
that underlay Japanese barriers to the approval of Western pharmaceuticals.
D. The Creation of Unnecessary and Unscientific Difference
Many of the comments, as discussed above, challenge the accuracy and
consistency of the OMB categories as a basis for collecting clinical data. An
important subset of these concerns was a recognition by both Pharmacia121 and
PhRMA122 that using the social categories of the OMB in the context of drug
development might lead to the creation of the perception of relevant differences
where in fact none existed. Such differences would present unnecessary barriers to
global drug development. Pharmacia noted that:
The first paragraph [of the Draft Guidance] states that the categories are not based on
scientific principles. It is understandable that the U.S. government wants to sort issues by
various socio/cultural groups. However, if there is no scientific basis for examining the
effects (either positive or negative) in these groups, doing so may provide an opportunity
for identifying differences where none exist. Collecting the data by these definitions is
123
one thing, using it to distinguish effects in different populations is another.

Pharmacia here recognizes that racial and ethnic data is a double edged sword.
While it may be used to open up Japanese markets, it also may be misused and
misinterpreted in a manner that obstructs markets. Once again, the OMB
categories are criticized as barriers to globalization. And yet, in all of this, the
calls for uniform globally applicable standards of race and ethnicity bring us back
to the ICH E5 Guidelines which characterize race as an intrinsic genetic attribute –
with all the problems and dangers that entails.

121. Id.
122. PhRMA, supra note 96.
123. PHARMACIA COMMENTS RE GUIDANCE, supra note 98.
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V. Conclusion — Harmonizing Race
The FDA responded to the comments124 and issued its final Guidance125 in
September, 2005. The final Guidance remained substantially the same as the
Draft. Among the significant revisions was added text that allowed the omission
of the characterization of Hispanic or Latino for international clinical trials, and a
change in the characterization of “Black, of African Heritage,” to “Black” for
studies conducted abroad.126 The Guidance continues to recommend the use of the
OMB categories when collecting data – even for studies conducted outside the
United States, but recognizes that “these categories may not adequately describe
racial and ethnic groups in foreign countries.”127 The FDA, therefore, does seem
to have been at least somewhat responsive to the concerns expressed by large
pharmaceutical companies that the categories not impede global research,
development and marketing. Nonetheless, the final Guidance makes no concession
toward the suggestions to adopt purportedly more genetically based classifications
of ancestry proposed by Genaissance and DNAPrint.
The story of ICH E5 and the FDA Guidelines reveals the complexity of
navigating distinct regulatory regimes in the context of increasingly globalized
drug markets. It points up the enduring conceptual power of race and ethnicity to
shape understandings of human populations in diverse venues. Of greatest
concern, perhaps, is that the drive to harmonize race also threatens to geneticize
race. Throughout this story, race and ethnicity are presented largely as barriers to
globalization – differences that need to be somehow overcome in order for markets
to grow. Harmonization, both as an explicit concern of the ICH and as the
unavoidable backdrop to the FDA Guidance, is providing the impetus to produce
regular, standardized categories of race and ethnicity. In both ICH E5 and in the
discussions surrounding the FDA Guidance, a prominent attribute of calls for
harmonization has been an appeal to genetics – whether as an “intrinsic” aspect of
race or as a component of “Biogeographical Ancestry.” These purportedly more
objective or scientific understandings of race and ethnicity as a function of genetics
are proposed as a means to stabilize the inconsistency of social categories and
provide a basis for unifying global markets. In the drive to harmonize international
drug development we must be careful to avoid adopting a harmonized conception
of race as genetic.
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